First Phase 1 Optogenetic Trials Should Be Conducted in People Who Are Dying

&
American Journal of Bioethics Neuroscience 5 (3):16-18 (2014)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

DOI

10.1080/21507740.2014.911216

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,386

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Selected Issues Related to the Conduct, Reporting, and Analysis of Phase I Trials.Marcelle Denise Winget - 1996 - Dissertation, The Johns Hopkins University
Clinical Trials and Scid Row: The Ethics of Phase 1 Trials in the Developing World.Jonathan Kimmelman - 2007 - Developing World Bioethics 7 (3):128-135.
Clinical trials and scid row: The ethics of phase 1 trials in the developing world.Jonathan Kimmelman - 2007 - Developing World Bioethics 7 (3):128–135.
Ethics at Phase 0: Clarifying the Issues.Jonathan Kimmelman - 2007 - Journal of Law, Medicine and Ethics 35 (4):727-733.
Deception in the Single-Blind Run-In Phase of Clinical Trials.Howard Mann - 2007 - IRB: Ethics & Human Research 29 (2).
The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials.Spencer Phillips Hey & Jonathan Kimmelman - 2014 - Kennedy Institute of Ethics Journal 24 (2):121-139.
Starting clinical trials of xenotransplantation--reflections on the ethics of the early phase.S. Welin - 2000 - Journal of Medical Ethics 26 (4):231-236.
Controlling Brain Cells With Light: Ethical Considerations for Optogenetic Clinical Trials.Frederic Gilbert, Alexander R. Harris & Robert M. I. Kapsa - 2014 - American Journal of Bioethics Neuroscience 5 (3):3-11.
Assisted Dying & Disability.Christopher A. Riddle - 2017 - Bioethics 31 (6):484-489.
Strategies to Minimize Risks and Exploitation in Phase One Trials on Healthy Subjects.Adil E. Shamoo & David B. Resnik - 2006 - American Journal of Bioethics 6 (3):W1-W13.
The loneliness of the dying.Norbert Elias - 1985 - New York: Continuum.
Are Phase 1 Trials Therapeutic? Risk, Ethics, and Division of Labor.James A. Anderson & Jonathan Kimmelman - 2012 - Bioethics 28 (3):138-146.
Efficacy Testing as a Primary Purpose of Phase 1 Clinical Trials: Is it Applicable to First-in-Human Bionics and Optogenetics Trials?Frederic Gilbert, Alexander R. Harris & Robert M. I. Kapsa - 2012 - American Journal of Bioethics Neuroscience 3 (2):20-22.
An intervention to improve cancer patients' understanding of early-phase clinical trials.Nancy E. Kass, Jeremy Sugarman, Amy M. Medley, Linda A. Fogarty, Holly A. Taylor, Christopher K. Daugherty, Mark R. Emerson, Steven N. Goodman, Fay J. Hlubocky & Herbert I. Hurwitz - 2009 - IRB: Ethics & Human Research 31 (3):1.
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (phase III) clinical trials are major obstacles to advances in health care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.

Analytics

Added to PP
2018-06-22

Downloads
9 (#1,224,450)

6 months
4 (#790,687)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Julian Savulescu
Oxford University

Citations of this work

Add more citations

References found in this work

Harm, ethics committees and the gene therapy death.J. Savulescu - 2001 - Journal of Medical Ethics 27 (3):148-150.

Add more references